Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.
作者信息
Johnson Julie A
机构信息
Department of Pharmacy Practice, Pharmaceutics and Medicine, Center for Pharmacogenomics, University of Florida, Gainesville, FL 32610-0486, USA.
出版信息
Circulation. 2008 Sep 23;118(13):1383-93. doi: 10.1161/CIRCULATIONAHA.107.704023.
Abstract
摘要
相似文献
1
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.心血管药物反应中的种族差异：药物遗传学的潜在作用。
Circulation. 2008 Sep 23;118(13):1383-93. doi: 10.1161/CIRCULATIONAHA.107.704023.
2
Pharmacogenetics and cardiovascular disease management.药物遗传学与心血管疾病管理
Hosp Med. 2004 Oct;65(10):594-8. doi: 10.12968/hosp.2004.65.10.16608.
3
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?一篇关于心血管疾病药物遗传学的系统综述：它是否准备好用于临床应用？
Eur Heart J. 2012 Jan;33(2):165-75. doi: 10.1093/eurheartj/ehr239. Epub 2011 Jul 30.
4
Clinical Implementation of Cardiovascular Pharmacogenomics.心血管药物基因组学的临床应用
Mayo Clin Proc. 2015 Jun;90(6):701-4. doi: 10.1016/j.mayocp.2015.04.011.
5
[Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases].[药物遗传学——心血管疾病治疗的新视角]
Kardiol Pol. 2004 Mar;60(3):304-8.
6
Pharmacogenetics of chronic cardiovascular drugs: applications and implications.慢性心血管药物的药物遗传学：应用与影响
Expert Opin Pharmacother. 2006 Aug;7(11):1417-27. doi: 10.1517/14656566.7.11.1417.
7
[Pharmacogenomics of cardiovascular pharmacology].[心血管药理学的药物基因组学]
Nihon Yakurigaku Zasshi. 2006 Sep;128(3):130-2. doi: 10.1254/fpj.128.130.
8
Pharmacogenomics and management of cardiovascular disease.药物基因组学与心血管疾病的管理
Nursing. 2011 Spring;41 Suppl:1-7. doi: 10.1097/01.NURSE.0000394517.13969.29.
9
Pharmacogenomics: the genetics of variable drug responses.药物基因组学：药物反应变异性的遗传学
Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820.
10
Pharmacogenomics and cardiology: improving treatment with existing drugs.药物基因组学与心脏病学：利用现有药物改善治疗
Pharmacogenomics. 2015;16(11):1223-6. doi: 10.2217/pgs.15.110.
引用本文的文献
1
Genetic Variation in Hydrochlorothiazide Response-Related Genes Among Hypertensive Individuals in Soweto, South Africa.南非索韦托高血压患者中氢氯噻嗪反应相关基因的遗传变异
Clin Transl Sci. 2025 Jul;18(7):e70302. doi: 10.1111/cts.70302.
2
Bottom-up Biomaterial strategies for creating tailored stem cells in regenerative medicine.用于在再生医学中创建定制干细胞的自下而上生物材料策略。
Front Bioeng Biotechnol. 2025 May 20;13:1581292. doi: 10.3389/fbioe.2025.1581292. eCollection 2025.
3
Bridging the United States population diversity gaps in clinical research: roadmap to precision health and reducing health disparities.弥合美国临床研究中的人口多样性差距：精准健康与减少健康差距的路线图。
Per Med. 2025 May 13:1-11. doi: 10.1080/17410541.2025.2504329.
4
Impact of Renin-Angiotensin-Aldosterone System (RAAS) Gene Polymorphism in Essential Hypertension and Antihypertensive Drug Therapy: A Review.肾素-血管紧张素-醛固酮系统（RAAS）基因多态性在原发性高血压及抗高血压药物治疗中的作用：综述
Int J Hypertens. 2025 May 1;2025:5530265. doi: 10.1155/ijhy/5530265. eCollection 2025.
5
Sub-Saharan Africa's Contribution to Clinical Trials in International Acute Coronary Syndromes and Heart Failure Guidelines.撒哈拉以南非洲地区对国际急性冠状动脉综合征和心力衰竭指南中临床试验的贡献。
JACC Adv. 2024 Dec 26;3(12):101383. doi: 10.1016/j.jacadv.2024.101383. eCollection 2024 Dec.
6
Genetic landscape of atopic dermatitis.特应性皮炎的遗传景观。
Curr Opin Allergy Clin Immunol. 2024 Oct 1;24(5):409-415. doi: 10.1097/ACI.0000000000001005. Epub 2024 Jun 24.
7
Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records.2010 年至 2019 年美国成年人抗高血压处方趋势及治疗指南更新后的变化：多中心电子健康记录分析。
J Am Heart Assoc. 2024 May 7;13(9):e032197. doi: 10.1161/JAHA.123.032197. Epub 2024 Apr 19.
8
Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease.富含人群的固有免疫变异体可能在癌症和心脏代谢疾病的交叉点确定候选基因靶点。
Front Endocrinol (Lausanne). 2024 Mar 21;14:1286979. doi: 10.3389/fendo.2023.1286979. eCollection 2023.
9
Synergy of Mutation-Induced Effects in Human Vitamin K Epoxide Reductase: Perspectives and Challenges for Allo-Network Modulator Design.突变诱导效应在人类维生素 K 环氧化物还原酶中的协同作用：全网络调节剂设计的观点和挑战。
Int J Mol Sci. 2024 Feb 7;25(4):2043. doi: 10.3390/ijms25042043.
10
Challenges in Clinical Research in Low and Middle Income Countries: Early Career Cardiologists' Perspective.低收入和中等收入国家临床研究面临的挑战：早期职业心脏病专家的观点。
Glob Heart. 2024 Jan 25;19(1):13. doi: 10.5334/gh.1293. eCollection 2024.
本文引用的文献
1
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.口服抗凝治疗起始阶段患者中，基因分型指导下的华法林剂量与标准华法林剂量的随机试验。
Circulation. 2007 Nov 27;116(22):2563-70. doi: 10.1161/CIRCULATIONAHA.107.737312. Epub 2007 Nov 7.
2
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.CYP2C9基因分型指导的华法林处方可提高抗凝治疗的有效性和安全性：一项前瞻性随机对照研究。
Clin Pharmacol Ther. 2008 Mar;83(3):460-70. doi: 10.1038/sj.clpt.6100316. Epub 2007 Sep 12.
3
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.CYP2C9和VKORC1 1173C/T基因多态性对华法林治疗的非裔美国人和欧美裔患者出血并发症风险的影响
Clin Pharmacol Ther. 2008 Feb;83(2):312-21. doi: 10.1038/sj.clpt.6100290. Epub 2007 Jul 25.
4
Pharmacogenetics of beta-blockers.β受体阻滞剂的药物遗传学
Pharmacotherapy. 2007 Jun;27(6):874-87. doi: 10.1592/phco.27.6.874.
5
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).维拉帕米缓释片治疗患者中影响添加群多普利血压反应的因素（来自国际维拉帕米缓释片/群多普利[INVEST]研究）
Am J Cardiol. 2007 Jun 1;99(11):1549-54. doi: 10.1016/j.amjcard.2007.01.029. Epub 2007 Apr 16.
6
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.β1和α2C肾上腺素能受体的协同多态性及其对心力衰竭患者左心室射血分数对β受体阻滞剂治疗反应的影响
Pharmacogenet Genomics. 2007 Apr;17(4):277-82. doi: 10.1097/FPC.0b013e3280105245.
7
Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation.日本房颤患者华法林治疗的严重出血并发症发生率
Circ J. 2007 May;71(5):761-5. doi: 10.1253/circj.71.761.
8
Evaluation of genetic factors for warfarin dose prediction.用于华法林剂量预测的遗传因素评估。
Clin Med Res. 2007 Mar;5(1):8-16. doi: 10.3121/cmr.2007.724.
9
Genetic-based dosing in orthopedic patients beginning warfarin therapy.开始华法林治疗的骨科患者基于基因的剂量确定。
Blood. 2007 Sep 1;110(5):1511-5. doi: 10.1182/blood-2007-01-069609. Epub 2007 Mar 26.
10
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.非裔美国人和高加索人中的华法林反应与维生素K环氧化物还原酶复合体1
Clin Pharmacol Ther. 2007 May;81(5):742-7. doi: 10.1038/sj.clpt.6100144. Epub 2007 Feb 28.
Zotero 插件